IRVINE, Calif., June 8, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company") announced today that its industry leading cryogenic logistics solutions, including cryogenic shipping, logistics support and chain of condition monitoring, are supporting Tissue Solutions ("Tissue Solutions") as it transports products from their global network of more than 100 locations. Tissue Solutions is a leading supplier of human bio specimens to the pharmaceutical and biotech industries worldwide, specializing in the supply of high quality, ethically sourced human tissue and bio fluids for clinical trial programs.
Tissue Solutions is utilizing Cryoport's logistics management platform, proprietary Cryoport Express® dry vapor dewars and advanced Smart Pak II™ condition monitoring systems to ship isolated human cells and cryopreserved cell lines from international collection sites to clients across the globe. The Smart Pak II™ Condition Monitoring System is engineered to work in tandem with Cryoport's data management platform, the Cryoportal™, which provides automated alerts regarding changes in required conditions, including deviations from estimated transit times, temperature excursions, potential temperature excursions, as well as shipper condition and openings. Cryoport's custom end-to-end solutions provides Tissue Solutions' cell lines with the most advanced cryogenic logistics solution anywhere including constant monitoring during the entire logistics process.
Morag McFarlane, CEO of Tissue Solutions stated, "We use Cryoport to ship isolated human cells and cryopreserved cell lines, including PBMCs and other immune cell subsets. Shipping at cryogenic temperatures with Cryoport's solution offers our clients the best option to minimize temperature fluctuations which can have a detrimental impact on cell integrity. Also, Cryoport's custom solutions significantly broaden our reach and the number of sites we can offer to our clients. Further, it affords our clients the option to select samples based on a wide range of specific donor demographic characteristics or screen multiple lots to find the sample that works best for their research, ensuring they get the specific samples they need, and are not restricted geographically."
Jerrell Shelton, CEO of Cryoport, said, "Cryoport is proud to be supporting Tissue Solutions, which is a leading supplier of ethically sourced human bio specimens. Tissue Solutions' services provide an indispensable link for a number of pharmaceutical and biotech companies for preclinical research and safety testing of drugs. Tissue Solutions depends on the support that only Cryoport can bring in supporting its highly successful services with Cryoport's advanced cryogenic logistics expertise and technology including our highly engineered and validated cryogenic cold chain shippers accompanied by crucial real-time and archived information."
About Tissue Solutions Limited
Tissue Solutions is a virtual biobank, sourcing ethically acquired, fully consented tissue from our extensive global network. Our collaborating partners include direct hospital sources, commercial biobanks, and charities, as well as prospective post-mortem organ and tissue collection agencies. We are an ISO 9001:2008 certified company, and offer a single access point for a wide range of diseased and normal tissues in fresh, frozen, and FFPE formats. We guarantee the quality of our samples, and continually review our suppliers for their product and service provision. Our products include: fresh human tissues & bio fluids, fresh human bloods & bio fluids, customized prospective collection, fresh human skin, banked human diseased & normal samples, freshly isolated human cells and primary cell lines, including PBMCs and FDA/EMEA panels of normal tissues. Our services include: Biomarker Development, Antibody Support, Histology & IHC, and Patient-derived Xenograft models. For more information, visit www.tissue-solutions.com.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Cryoport actively supports points-of-care, CRO's, central laboratories, pharmaceutical companies, contract manufacturers and university researchers. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cryoport-signs-strategic-agreement-to-support-tissue-solutions-transportation-of-human-cells-and-cryopreserved-cell-lines-300281072.html
SOURCE Cryoport, Inc.